ImproveCareNow Retrospective_Research


Disparities in height at diagnosis of pediatric IBD

A:

Purpose: The purpose of this study is to evaluate patient characteristics and treatment patterns that may be associated with diagnostic delay.

Specific Aims:

  1. Determine the variation in height z-score at diagnosis
  2. Determine the association between height z-score at diagnosis and socio-demographic information
  3. Determine association between growth stunting at diagnosis and variation in treatment selection and disease outcomes

Contact: Joann Samalik


The Association between Erythema Nodosum (EN) and Pyoderma Gangrenosum (PG) in Pediatric Inflammatory Bowel Disease (IBD)

A:

Purpose: The purpose of this study is to describe the pediatric IBD population in the ICN database with skin findings of Erythema Nodosum (EN) and Pyoderma Gangrenosum (PG).

Specific Aims:

Primary aims:

--To estimate the incidence of EN and PG in pediatric patients diagnosed with IBD in the database.

--To describe the demographics, disease presentation, natural history and treatments of this patient cohort with both IBD and EN/PG.

Secondary aim:

--To identify factors that may predispose pediatric patients diagnosed with IBD to develop related cutaneous manifestations.

Study Period: The timeline for this study will be approximately 6 to 12 months.

Contact: Brad Pasternak


Assessing Provider Prescribing habits of Intravenous Anti-TNFs and Assessing Outcomes Related to Non-Medical Switches from the Originator to a Biosimilar

A:

Principal Investigator: Ross Maltz, MD; Nationwide Children's Hospital

Overall Study Question: Evaluate variation in prescribing habits of IV anti-TNF therapies across the pediatric IBD community. Evaluate the safety and efficacy of non-medical switches from the originator to a biosimilar

Specific Aims:

  1. To evaluate infliximab use over time for patients who are anti-TNF naïve, to determine if biosimilar use is increasing nationally, variation amongst practices, geographic regions, by commercial vs Medicaid insurance, and race.
  2. To evaluate long-term clinical outcomes of pediatric patients initiated on an infliximab biosimilars vs the originator.
  3. Evaluate how often switching from the originator to a biosimilar are occurring within the ICN Network.  Determine if non-medical switching adversely affects clinical outcomes in pediatric IBD patients including the impact upon clinical remission in addition to anti-TNF drug and antibody levels. Evaluate how often patients are switching back to the originator or to a different therapy class.

Study Period: Beginning in May 2022

Contact: Ross Maltz, MD


Frequency of Normal Laboratory Workup in Pediatric Patients Diagnosed with Inflammatory Bowel Disease

A:

Purpose: Our primary aim is to examine the frequency of normal laboratory results (i.e. hemoglobin, c-reactive protein, erythrocyte sedimentation rate, albumin, and fecal calprotectin) in the at the time of IBD diagnosis, prior to initiating medical therapy. A secondary aim will be to determine the variation in frequency of normal labs between subgroups of patients (disease type, age at diagnosis, race, ethnicity, gender, etc.).

Primary Outcome: The proportion of patients with normal laboratory findings at diagnosis, prior to initiating medical therapy.

Study Period: March 2022 - August 2023

Contact: Nicholas Litchin, Jeremy Adler


Real-world Evidence for the Effectiveness and Safety of Ustekinumab Treatment in Children with Crohn’s Disease (REALITI)

A:

 

Title: Real-world Evidence for the Effectiveness and Safety of Ustekinumab Treatment in Children with Crohn’s Disease: A Retrospective Cohort Study using the ImproveCareNow Registry Data

PIs:

Steve Steiner, MD, REALITI Co-Principal Investigator, Riley Children’s Hospital 

Shehzad Saeed, MD, REALITI Co-Principal Investigator, ImproveCareNow & Dayton Children’s Hospital 

Jeremy Adler, MD, REALITI Co- Principal Investigator, University of Michigan – C.S. Mott Children’s Hospital

Purpose: The primary objective of this study is to evaluate the clinical effectiveness of ustekinumab by determining the clinical remission rate in pediatric patients with moderately to  severely active Crohn’s Disease (CD) in the ICN registry who were treated with ustekinumab.

Primary Outcome: This study will generate knowledge about the use of ustekinumab in the management of pediatric Crohn’s Disease. The results of this study will be included as part of a Janssen submission to the FDA for the approval of the use of ustekinumab in pediatric patients, as they plan a phase 3 clinical trial of ustekinumab. In addition, the inclusion of RWE from ICN could help facilitate the approval of ustekinumab and other  new  drugs  for  IBD,  making  new  IBD treatments accessible  to  pediatric  patients sooner, enabling better outcomes for our patients. If the ICN-Janssen REALITI Study is successful, other new IBD drugs could be studied in a similar way, having a major impact on the health of our patients as well as on the sustainability of ICN.

Funding Source: Janssen has provided funding to ICN to perform this study; however, it is important to note that this  is  an  observational study with  a  retrospective  chart  review  and not an interventional study.

Study Period: The study will take approximately 9 to 18 months to complete from implementation to publication.

Recruitment Status: All eligible patients have been identified via the ICN  Registry, the 72 ICN centers with eligible patients have been invited to participate.

Contact: [email protected]


Prevalence and Outcomes of Pediatric Patients with Very Early-Onset IBD (VEO-IBD)

A:

Mallory_Chavannes_VEO-IBD.png

Purpose: Very early-onset inflammatory bowel disease (VEO-IBD) presents in children less than 6 years of age. These patients have more extensive, progressive and medically refractory disease making it phenotypically distinct from older-onset pediatric and adult IBD.

The incidence of pediatric IBD is increasing rapidly but there is no specific data for the US population. Given the paucity of information, our objective was to determine the prevalence of VEO-IBD within the ImproveCareNow (ICN) Network registry, which accounts for more than 50% of all pediatric IBD patients in the US.

Primary Outcome: Our primary outcomes are frequency of clinical remission in the VEO-IBD population and time to clinical remission. Clinical remission will be defined by normal physician global assessment (PGA), PCDAI, PUCAI, ESR or CRP.

Secondary Outcome: Our secondary outcomes will be frequency of and time to surgery (specifically, colectomy or creation of ileostomy or colostomy) and frequency of sustained corticosteroid free remission, one of the major outcomes tracked by the ImproveCareNow Network.

Study Period: June 2020-July 2021

Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment at this time.

Contact: ImproveCareNow Research 


Phenotype of Pediatric IBD in Asian American Children

A:

17_Patel_Phenotype.png

Purpose: Describe the phenotype of IBD in pediatric patients of Asian American ethnicity

Primary Outcome: Our hypothesis is that the phenotype of pediatric IBD in Asian American children is unique compared to the general population.

Funding Source: N/A

Study Period: Jan 2019-June 2020

Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment at this time.

Contact: Ashish Patel 


Pediatric Fistulizing Crohn’s Disease Study

A:

16_Adler_Pediatric_Fistulizing.png

Purpose: Crohn’s disease causes fistulas, which are abnormal openings from the bowel to adjacent structures such as the skin, bladder, genitals, or to other loops of bowel.  Fistulas frequently lead to serious and sometimes debilitating complications. 

Fistulas have a major negative impact on quality of life of children and their caregivers and are highly distressing.  Fistulas can cause many complications including fecal incontinence, infertility, chronic draining wounds, abscesses, and severe infections of the bladder, kidneys, uterus, or other internal structures. Fistulas are difficult to treat, requiring expensive medications and surgery, and treatments are often not effective. Strategies are needed to prevent fistulas from developing in the first place.

This study is designed to answer several important questions:

  • What are the characteristics of children who at the greatest risk for developing fistulas? 
  • Does early selection of therapy alter the risk for fistulas among children? 
  • Does the risk of fistula among children change with the duration of disease?

Primary Outcomes: 

  • Developing perianal fistula
  • Time to perianal fistula development

Secondary Outcomes:

  • Medication use
  • Surgery

Funding Source: Shaevsky Family Research Fund for Crohn’s Disease

Study Period: 2013-2022

Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment at this time.

Contact: ImproveCareNow Research


Uveitis in a Multicenter Pediatric IBD Population: Results from the ICN Network

A:

22_Schaefer_Uveitis.png

Purpose: Uveitis has long been recognized as an extraintestinal manifestation of inflammatory bowel disease. The prevalence of uveitis in the pediatric IBD population has only been studied in small groups of IBD patients in single-center studies. Evaluating the prevalence of uveitis in the ImproveCareNow database will allow us to gain a much better appreciation of the prevalence of uveitis in the pediatric IBD population and learn more about possible risk factors.

Primary/Secondary Outcomes:

  • Primary Outcome: Assess the prevalence of uveitis in the pediatric IBD population
  • Secondary Outcome: Find associated risk factors for uveitis in the pediatric IBD population

Study Period: Patients enrolled between 2006 and 2016

Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment at this time.

Contact: Marc E. Schaefer, MD, MPH

Additional Links

Poster - Uveitis in a Multicenter Pediatric IBD Population: Results from the ICN Network


← Previous  1  2

Built by Veracity Media on NationBuilder